



16 June 2026

ASX Announcement

Investor Presentation - Asia Dengue Summit

MELBOURNE Australia, 16 June 2026: Australian antiviral drug development company, Island Pharmaceuticals Ltd (**ASX: ILA; Island or the Company**) advises that Dr. David Foster CEO and Managing Director of Island is presenting new analysis of data from PROTECT study at the 9th Asia Dengue Summit in Singapore at the Orchard Hotel Singapore today at 4:30pm (SGT). The investor presentation is included in this announcement.

- Ends -

Approved for release to the ASX by:

David Foster (CEO and Managing Director)
Island Pharmaceuticals Limited
info@islandpharmaceuticals.com

Investors and media, for further information, please contact:

Henry Jordan
Six Degrees Investor Relations
+61 (0) 431 271 538
henry.jordan@sdir.com.au

About Island Pharmaceuticals

Island (ASX: ILA) is focused on areas of unmet need for drugs that can address urgent viral diseases, public health or biosecurity threats. The Company is executing a dual development strategy for its assets, ISLA-101 and Galidesivir.

ISLA-101 has a well-established safety profile, being repurposed for the prevention and treatment of dengue fever and other mosquito (or vector) borne diseases. Galidesivir is a clinical-stage antiviral molecule with a broad spectrum of activity in over 20 RNA viruses, including high-priority threats such as Ebola, Marburg, MERS, Zika and Yellow fever – viruses with significant unmet medical needs and that may contribute to national security threats.

Island encourages all current investors to go paperless by registering their details with the Company's share registry, Automatic Registry Services, whose contact info is housed on the Shareholder Services page of the Company's website.

Visit www.islandpharmaceuticals.com for more on Island.



ISLAND

PHARMACEUTICALS

COMBATTING URGENT VIRAL DISEASE THREATS

Asia Dengue Summit

Dr David Foster, CEO & Managing Director

June 2026

ASX: ILA



Island Pharmaceuticals (ASX: ILA)

Two programs targeting infectious diseases



Two, well advanced clinical stage programs



Phase 2a PROTECT clinical trial in dengue complete with ISLA-101



Major market potential via both programs



Positive FDA feedback on Animal Rule regulatory path for galidesivir



Both assets have Priority Review Voucher potential



Multiple near term clinical trial, operational and regulatory catalysts

ISLA-101 – BROAD ACTIVITY EVIDENT


- ISLA-101 has demonstrated broad anti-viral activity in in-vitro models
- Demonstrated potent anti dengue-1 activity in in-vitro models using fresh human cells
- Protective in dengue fever and Zika in animal models
- Shown to prevent death in 70% of subjects in extremely lethal animal models
- Increasing concentrations of ISLA-101 prevent death induced by an otherwise lethal dengue fever infection
- Initially developed as a cancer drug by large pharma company- never approved anywhere
- 48 human clinical studies completed in other indications



Demonstrated activity against flaviviruses (subgroup of arboviruses) in models of infection



PREVENTING ANIMAL DEATHS FROM LETHAL DENGUE AND PROTECTIVE AGAINST ZIKA







PHASE 2A (PROTECT) PROOF OF CONCEPT

- Single dose proof of concept study in a dengue human infection model at SUNY Upstate
- Phase 2a (prophylactic) subjects dosed initially (3 active: 1 placebo)
- Safety Review Committee review highlighted:
 - Administering ISLA-101 was safe
 - Study achieved appropriate ISLA-101 blood concentrations
 - Dosed subjects exhibited evidence of antiviral activity versus control
 - Unanimous decision to advance treatment cohort
- 2b (treatment) cohort administered ISLA-101 (8 active: 2 placebo)
- Unpublished data to follow (manuscript in preparation)

Phase 2A: Prophylactic (preventative) cohort







Phase 2B: Therapeutic (treatment) cohort



PHARMACOKINETICS OF ISLA-101 IN TREATED PARTICIPANTS






Plasma concentration-time profiles of ISLA-101 across dosing in study participants.






VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- RNAEMIA






VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- VIREMIA









VIROLOGIC CHARACTERISTICS OF ISLA-101 TREATED SUBJECTS- NS1




Spearman Correlation of Peak RNAemia or Viremia and day of RNAemia onset in Treatment Cohort





Earlier ISLA-101 Treatment Leads to Lower Cumulative Viremia





SUMMARY OF SIGNS & SYMPTOMS

Summary of Signs and Symptoms Associated with Dengue Virus Infection over 29 days from Inoculation - by Group (Full Analysis Set)

Subjects experiencing at least one:	Control (N=3) n(%)	Prophylaxis & Treatment (N=3) n(%)	Delayed treatment (N=8) n(%)	All subjects (N=14) n(%)
Signs and symptoms associated with dengue virus infection	3/3(100)	3/3(100)	8/8(100)	14/14(100)
Abdominal Pain	2/3(66.7)	0/3(0.0)	5/8(62.5)	7/14(50.0)
Bone Pain	0/3(0.0)	0/3(0.0)	1/8(12.5)	1/14(7.1)
Eye Pain	2/3(66.7)	1/3(33.3)	7/8(87.5)	10/14(71.4)
Fatigue	3/3(100)	2/3(66.7)	7/8(87.5)	12/14(85.7)
Fever $\geq 38^{\circ}$ C (100.4 $^{\circ}$ F)	2/3(66.7)	0/3(0.0)	2/8(25.0)	4/14(28.6)
Headache	3/3(100)	2/3(66.7)	8/8(100)	13/14(92.9)
Joint Pain	2/3(66.7)	1/3(33.3)	5/8(62.5)	8/14(57.1)
Muscle Pain (Myalgia)	2/3(66.7)	2/3(66.7)	7/8(87.5)	11/14(78.6)
Nausea	2/3(66.7)	1/3(33.3)	5/8(62.5)	8/14(57.1)
Rash	2/3(66.7)	2/3(66.7)	7/8(87.5)	11/14(78.6)
Vomiting	1/3(33.3)	0/3(0.0)	1/8(12.5)	2/14(14.3)



POSITIVE PHASE 2 TOP-LINE RESULTS:


- Achieved desired plasma concentration of ISLA-101
- Positive top-line results advocate for ongoing clinical development of ISLA-101 in dengue
- ISLA-101 delivered meaningful reduction in viremia (viral load) and symptoms in preventative cohort
- Treatment cohort demonstrated signals of drug effect including a negative correlation between initiation of viremia and peak viremia
- Encouraging results support advancing to future clinical trials in both prevention and treatment studies
- Efforts underway to optimize oral formulation for prophylaxis and IV formulation for treatment



CLINICAL TRIAL AND REGULATORY PATHWAY

A defined clinical and regulatory route based on Phase 2a/b study results

- Two likely pathways depending on Phase 2a/b results
- Discussions advancing with multiple potential strategic partners for additional phase 2 and 3 clinical trials



Ongoing engagement with US FDA to be undertaken during these initiatives



ISLAND
PHARMACEUTICALS

Island Pharmaceuticals

ASX: ILA



dfoster@islandpharmaceuticals.com



islandpharmaceuticals.com



[@IslandPharma](https://twitter.com/IslandPharma)



[Island Pharmaceuticals](https://www.linkedin.com/company/island-pharmaceuticals)